SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC is trending as investors react to the NOAA determination that the companys deep-seabed mining application is in full compliance, fueling community anticipation for accelerated permitting and long-term supply dominance. The broader conversation centers on the stock as a conviction-based play on the critical minerals supercycle, with community members actively discussing the strategic importance of domestic deep-sea mining to meet rising demand from AI and EV infrastructure.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk is trending after reporting explosive earnings that significantly exceeded estimates, driven by a massive surge in AI-related data center demand. While some investors are engaging in profit-taking following the stock's parabolic climb, the community is actively debating whether the company's strong guidance, record margins, and new multibillion-dollar share buyback program signal a sustained supercycle or an unsustainable bubble.

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo Chaparro on December 31, 2014 and is headquartered in Boston, MA.

Cue Biopharma Inc

Cue Biopharma is seeing massive volatility and high trading volume driven by a milestone payment from its Boehringer Ingelheim partnership, even as retail sentiment remains divided over the company's upcoming reverse stock split vote. Traders are actively debating whether the price action represents a legitimate fundamental catalyst or a speculative pump-and-dump setup, with many closely watching the stock for potential short-squeeze activity.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending after reporting record quarterly revenue and EPS, supported by robust iPhone demand and a massive new share buyback authorization. While investors are actively debating the impact of rising memory costs and the upcoming CEO transition to John Ternus, bullish sentiment remains focused on the company's strong services growth and potential long-term upside from AI integration.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit shares are surging after the company delivered a massive first-quarter beat, exceeding revenue and earnings estimates while providing strong guidance. The community remains highly focused on the stock's potential for a short squeeze and its long-term AI data licensing prospects, though some investors remain cautious about potential post-earnings volatility.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox is facing significant downward pressure and intense community scrutiny following a major earnings miss, a downward revision of future bookings, and ongoing concerns regarding child safety and platform moderation. Investors are divided, with some viewing the sharp decline as a buying opportunity in a growth platform, while others are warning of continued volatility and fundamental risks.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

Atlassian shares are surging following a robust quarterly performance that exceeded revenue and earnings expectations, bolstered by strong cloud growth and accelerated AI monetization. The community is actively debating whether this result signals a durable recovery for enterprise software or if the stock remains vulnerable to ongoing valuation and competition concerns.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global Holdings is trending following a strong first-quarter report where the company beat revenue estimates and raised its forward guidance, fueling community optimism around its accelerating AI-driven marketing growth. Investors are actively debating the sustainability of its 50% year-over-year revenue growth and debating the stock's potential for a short squeeze as they look for signs of a long-term re-rating phase.

Akanda Corp. is a cannabis cultivation, manufacturing, and distribution company, which engages in the provision of premium quality and ethically sourced medical cannabis products to patients. The company cultivates and processes natural cannabis at facilities in the Kingdom of Lesotho, Africa and intend to supply medicinal-grade cannabis biomass, cannabis flower, and cannabis concentrates to wholesalers. It also imports and sells medical cannabis-based products. The company was founded on July 16, 2021 and is headquartered in New Romney, the United Kingdom.

Akanda Corp

Akanda Corp is experiencing extreme volatility and a massive short squeeze, driven by its ultra-low float and a borrow rate nearing 1,000%, which is forcing shorts to cover or face liquidation. Community sentiment is divided between retail bulls who are cheering the parabolic price action and skeptical traders warning of a potential rug-pull due to the company's history of reverse splits and weak fundamentals.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is currently trending as investors weigh a significant earnings beat against concerns over potential future dilution, highlighted by a freshly filed shelf offering and a restructured DOE loan. The community remains sharply divided, with bulls pointing to the long-term potential of the R2 production ramp and strategic partnerships, while bears emphasize ongoing cash burn, executive compensation, and the heavy reliance on Amazon for revenue.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Anthem (NASDAQ:ANTX) Downgraded to "Sell" Rating by Wall Street Zen

Wall Street Zen downgraded Anthem from a "hold" rating to a "sell" rating in a research report on Saturday...

Anthem (NASDAQ:ANTX) Upgraded by Wall Street Zen to "Hold" Rating

Wall Street Zen raised shares of Anthem to a "hold" rating in a report on Saturday...

Anthem (NASDAQ:ANTX) Stock Price Up 1.2% - Still a Buy?

Anthem (NASDAQ:ANTX) Shares Up 1.2% - Still a Buy...

AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the initiation of a Phase 2 investigator-initiated clinical trial evaluating the safety, efficacy, and...

AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry...

AN2 Therapeutics Stock Cools Off After 90% Rally

AN2 Therapeutics stock dips in premarket after a 90% surge tied to a $40 million equity raise.read more...

Power Hour Surge: Biotech Cash Floods, Energy Breakouts, and AI Bets Drive the Stocks to Watch into the Close

As Wall Street heads into the final stretch of the trading day, capital flows into biotech financing, clean energy, and emerging technology platforms are shaping the stocks traders are watching most closely into the close and after-hours session. $EONR, $SAFX, $KBLB, $HIMS, $MDCX, $ANTX, $NVO, $MDCX, $RLMD, $SLDB, $ANTX, $EDIT, $DDD

AN2 Therapeutics Stock Jumps 90% Monday: What's Driving The Action?

AN2 Therapeutics Inc (NASDAQ: ANTX) shares are surging Monday afternoon after the company announced a $40 million private placement financing.read more...

<ul class="summary-bullets"><li>AN2 Therapeutics is expected to sell more than eight million shares of common stock at $2.85 per share.</li><li>The private placement includes participation from institutional investors such as Coastlands Capital, Commodore Capital, and Vivo Capital.</li><li>The stock has gained more than&nbsp;500% over four sessions since the company announced positive results for its blood cancer treatment.</li></ul>Shares of AN2 Therapeutics (ANTX) surged more than 110% on Monday, after the clinical-stage biopharmaceutical company announced that it signed a securities purchase agreement for a private placement expected to raise about $40 million in gross proceeds.<a href="https://stocktwits.com/symbol/ANTX">ANTX shares</a> recorded their biggest-ever intraday gains.As part of the deal, AN2 Therapeutics will sell 8.25 million shares of common stock at $2.85 per share, which was also the stock’s closing price on Friday. The company also offered investors the option to purchase pre-funded warrants to acquire up to 5.79 million additional shares at nearly the same price, with an exercise price of&nbsp;$0.00001 per share.The private placement is expected to close on March 10, 2026, and includes participation from institutional investors such as Coastlands Capital, Commodore Capital, and Vivo Capital, along with other new and existing shareholders. AN2 Therapeutics did not disclose how it plans to use the proceeds from the offering.<h2 class="st-heading-2">500% Rally After Epetraborole Update</h2>The stock has been on an extraordinary rally, adding nearly 500% over four sessions since the company announced plans to further develop its drug epetraborole into a Phase 2 proof-of-concept study for patients with Polycythemia Vera (PV) who rely on phlebotomy treatments.PV is a blood cancer that causes the bone marrow to produce too many red blood cells, increasing the risk of serious complications such as blood clots.Last week, AN2 Therapeutics said that its oral epetraborole produced consistent and sustained reductions in hematocrit across several studies involving healthy volunteers and other patient groups. The company expects to begin the Phase 2 study in the third quarter of 2026 and plans to provide initial trial updates by the following quarter.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits remained ‘extremely bullish’ over the past 24 hours, amid ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/ANTX_jpg_31ad151992.webp" alt="ANTX.jpg">One user highlighted the various resistance levels, speculating that the stock could climb as high as $108.<stembedurl>https://stocktwits.com/M105/message/647014265</stembedurl>However, another expressed confusion over the “bullish excitement.”<stembedurl>https://stocktwits.com/Tradeforlosses/message/647018987</stembedurl>Year-to-date, the stock has gained more than 400%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/iran-warns-of-crude-hitting-200-a-barrel-if-energy-infrastructure-is-targeted-report/cZdVpreRIIr">Iran Warns Of Crude Hitting $200 A Barrel If Energy Infrastructure Is Targeted: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ANTX Stock Records Biggest Ever Single Day Gain, Surges 500% Over Past Four Sessions – What Triggered This Smashing Rally?

AN2 Therapeutics shares more than doubled in value on Monday after the company announced a private placement to raise about $40 million.

Equity

AN2 Therapeutics Announces $40 Million Private Placement Financing

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced that it has...

AN2 Therapeutics, Inc. operates as a global health biopharmaceutical company. The firm focuses on modern biomedical and drug development to provide transformational medicines for patients suffering from infectious diseases. The company was founded by Eric Easom, George Harrison Talbot, Joseph S. Zakrzewski and Michael R.K. Alley in 2017 and is headquartered in Menlo Park, CA.

ANTX
AN2 Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ANTX News

ANTXAN2 Therapeutics Inc